Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
28.01
-0.50 (-1.77%)
At close: Jul 6, 2026, 4:00 PM EDT
28.65
+0.64 (2.28%)
Pre-market: Jul 7, 2026, 4:09 AM EDT
Genmab Employees
Genmab had 3,088 employees as of March 31, 2026. The number of employees increased by 450 or 17.06% compared to the same quarter last year.
Employees
3,088
Change
450
Growth
17.06%
Revenue / Employee
$1,263,277
Profits / Employee
$265,868
Market Cap
17.14B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 3,088 | 450 | 17.06% |
| Dec 31, 2025 | 2,973 | 339 | 12.87% |
| Sep 30, 2025 | 2,681 | 46 | 1.75% |
| Jun 30, 2025 | 2,639 | 113 | 4.47% |
| Mar 31, 2025 | 2,638 | 352 | 15.40% |
| Dec 31, 2024 | 2,634 | 430 | 19.51% |
| Sep 30, 2024 | 2,635 | 503 | 23.59% |
| Jun 30, 2024 | 2,526 | 511 | 25.36% |
| Mar 31, 2024 | 2,286 | 440 | 23.84% |
| Dec 31, 2023 | 2,204 | 544 | 32.77% |
| Sep 30, 2023 | 2,132 | 572 | 36.67% |
| Jun 30, 2023 | 2,015 | 570 | 39.45% |
| Mar 31, 2023 | 1,846 | 537 | 41.02% |
| Dec 31, 2022 | 1,660 | 448 | 36.96% |
| Sep 30, 2022 | 1,560 | 424 | 37.32% |
| Jun 30, 2022 | 1,445 | 416 | 40.43% |
| Mar 31, 2022 | 1,309 | 438 | 50.29% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 7,807 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Insmed | 1,664 |
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
GMAB News
- 14 hours ago - Genmab says EC grants marketing authorization for Tepkinly combo - TheFly
- 15 hours ago - Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire
- 4 days ago - Genmab price target raised to $40 from $38 at H.C. Wainwright - TheFly
- 6 days ago - Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial - WSJ
- 7 days ago - Genmab (GMAB) Reports Positive Phase 3 Trial Results for Epcoritamab - GuruFocus
- 7 days ago - Genmab announces topline results from EPCORE DLBCL-4 trial - TheFly
- 7 days ago - Genmab reports ‘positive’ Phase 3 results from EPCORE DLBCL-4 trial - TheFly
- 7 days ago - Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival - GlobeNewsWire